Suggested Treatment Regimens

Question 1

CLL/SLL without del (17p)/ TP53 mutation (Preferred) First Line

Answer 1

Acalabrutinib ± obinutuzumab (category 1)

Question 2

CLL/SLL without del (17p)/ TP53 mutation (Preferred) First Line

Answer 2

Venetoclax + obinutuzumab (category 1)

Question 3

CLL/SLL without del (17p)/ TP53 mutation (Preferred) First Line

Answer 3

Zanubrutinib (category 1)

Question 4

CLL/SLL without del (17p)/ TP53 mutation (Other recommended regimens) First Line

Answer 4

Ibrutinib (category 1 )

Question 5

CLL/SLL without del (17p)/ TP53 mutation (Other recommended regimens) (First Line)

Answer 5

Bendamustine + anti-CD20 mAb

Question 6

CLL/SLL without del (17p)/ TP53 mutation (Other recommended regimens) (First Line)

Answer 6

chlorambucil + obinutuzumab

Question 7

CLL/SLL without del (17p)/ TP53 mutation (Other recommended regimens) (First Line)

Answer 7

obinutuzumab

Question 8

CLL/SLL without del (17p)/ TP53 mutation (Other recommended regimens) (First Line)

Answer 8

high dose methylprednisolone + rituximab or obinutuzumab (category 2B; category 3 for patients < 65 y w/o significant comorbidities)

Question 9

CLL/SLL without del (17p)/ TP53 mutation (Other recommended regimens) (First Line)

Answer 9

ibrutinib + obinutuzumab (category 2B)

Question 10

CLL/SLL without del (17p)/ TP53 mutation (Other recommended regimens) (First Line)

Answer 10

ibrutinib + rituximab (category 2B)

Question 11

CLL/SLL without del (17p)/ TP53 mutation (Other recommended regimens) (First Line)

Answer 11

ibrutinib + venetoclax (category 2B)

Question 12

CLL/SLL without del (17p)/ TP53 mutation (Useful in certain circumstances) (First Line)

Answer 12

(consider for IGHV-mutated CLL in pts age <65 y w/o sig comorbidities)
FCR (fludarabine, cyclophosphamide, rituximab)

Question 13

CLL/SLL with del (17p)/TP53 mutation (Preferred) (First Line)

Answer 13

acalabrutinib ± obinutuzumab

Question 14

CLL/SLL with del (17p)/TP53 mutation (Preferred) (First Line)

Answer 14

venetoclax + obinutzumab

Question 15

CLL/SLL with del (17p)/TP53 mutation (Preferred) (First Line)

Answer 15

zanubrutinib

Question 16

CLL/SLL with del (17p)/TP53 mutation (Other recommended regimens) (First Line)

Answer 16

alemtuzumab ± rituximab

Question 17

CLL/SLL with del (17p)/TP53 mutation (Other recommended regimens) (First Line)

Answer 17

HDMP + rituximab

Question 18

CLL/SLL with del (17p)/TP53 mutation (Other recommended regimens) (First Line)

Answer 18

ibrutinib

Question 19

CLL/SLL with del (17p)/TP53 mutation (Other recommended regimens) (First Line)

Answer 19

obinutuzumab

Question 20

CLL/SLL with del (17p)/TP53 mutation (Other recommended regimens) (First Line)

Answer 20

ibrutinib + venetoclax